Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 5/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3696080 | 0.88 | HTR2C (0.33) | PLA2G7POLBMAP4K1LMNAPIM1 | |
| SCHEMBL4125425 | 0.87 | ALDH1A1 (0.36) | POLBSMN1; SMN2ALDH1A1TDP1KDM4E | |
| SCHEMBL3696085 | 0.87 | MAP4K1 (0.32) | PLA2G7POLBMAP4K1LMNAPIM1 | |
| SCHEMBL4125990 | 0.83 | MAPT (0.38) | POLBMAP4K1LMNAPIM1SMN1; SMN2 | |
| SCHEMBL4129846 | 0.81 | ALDH1A1 (0.33) | LMNAALDH1A1KMT2AKDM4E | |
| SCHEMBL3807952 | 0.80 | MAPT (0.33) | LMNASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL3696083 | 0.79 | HPGD (0.32) | MAP4K1LMNAPIM1ALDH1A1KMT2A | |
| SCHEMBL4131857 | 0.79 | MAPT (0.31) | SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL4131683 | 0.79 | EDNRA (0.40) | SMN1; SMN2KMT2APTGDR2 | |
| SCHEMBL4120389 | 0.79 | HTR1A (0.33) | POLBMAP4K1LMNAPIM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | PLA2G7 162/4885POLB 4579/4885MAP4K1 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.